FibroBiologics – Fibroblasts – The Regenerative Medicine That Will Replace Stem Cells
Dr. Hamid Khoja, Chief Scientific Officer at FibroBiologics, a regenerative medicine company developing treatment for chronic diseases using fibroblasts, talks about what fibroblasts are and how it could replace stem cell technology. The company’s indication of focus is multiple sclerosis and their fibroblast technology has demonstrated the ability to remyelinate nerve cells in pre-clinical studies. Small human efficacy studies have thus far demonstrated that treatment with fibroblasts helps improve the cognition and finger dexterity of MS patients.
Frequently Asked Questions
What is the main topic discussed in this episode of Health Professional Radio?
This episode covers important developments in healthcare, including updates on Treatment. Health Professional Radio brings you expert insights and analysis on the latest medical news affecting healthcare professionals and patients alike.
How can healthcare professionals benefit from this information?
Healthcare professionals can stay informed about the latest developments in Treatment and related fields, enabling them to provide better patient care. Staying current with medical news helps clinicians make evidence-based decisions in their practice.
Where can I find more information about Treatment?
For more detailed information, listen to the full episode on Health Professional Radio and visit hpr.fm for additional resources. You can also subscribe to our podcast for regular updates on healthcare news and expert interviews.
Key Takeaways
- Key Point: Hamid Khoja, Chief Scientific Officer at FibroBiologics, a regenerative medicine company developing treatment for chronic diseases using fibroblasts, talks about what fibroblast…
- Key Point: Small human efficacy studies have thus far demonstrated that treatment with fibroblasts helps improve the cognition and finger dexterity of MS patients. Dr.
- Key Point: Hamid Khoja, Chief Scientific Officer, earned his Ph.D.
- Key Point: in Molecular Biology at Boston University.
- Key Point: He achieved the Dean’s List at Stanford University and received a Bachelor of Science from University of Southern California.
Dr. Hamid Khoja, Chief Scientific Officer, earned his Ph.D. in Molecular Biology at Boston University. He achieved the Dean’s List at Stanford University and received a Bachelor of Science from University of Southern California. He has a combined experience of 26 years developing genomic, proteomics, and epigenetics assays, tools, and protocols, for use in drug discovery/development, and clinical diagnostics.
Medical Disclaimer
The information provided on this website is for general informational purposes only and is not intended as medical advice. Always consult with a qualified healthcare professional for medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.



